Sökning: WFRF:(Solbu Dag)
> (2020) >
Everolimus Initiati...
-
Gustafsson, FinnUniversity of Copenhagen,Copenhagen University Hospital,Rigshosp, Denmark; Univ Copenhagen, Denmark
(författare)
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
LIPPINCOTT WILLIAMS & WILKINS,2020
-
11 s.
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:4f96f99b-ca04-4eb7-9dac-42f0df5c560d
-
https://lup.lub.lu.se/record/4f96f99b-ca04-4eb7-9dac-42f0df5c560dURI
-
https://doi.org/10.1097/TP.0000000000002702DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-165665URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
BACKGROUND: A calcineurin inhibitor (CNI)-free immunosuppressive regimen has been demonstrated to improve renal function early after heart transplantation, but long-term outcome of such a strategy has not been well described. METHODS: In the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with reduced-exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 posttransplant or (2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients were followed up at 5-7 years posttransplant. RESULTS: Mean measured glomerular filtration rate was 74.7 mL/min and 62.4 mL/min with everolimus and CNI, respectively. The mean difference was in favor of everolimus by 11.8 mL/min in the intent-to-treat population (P = 0.004) and 17.2 mL/min in the per protocol population (n = 75; P < 0.001). From transplantation to last follow-up, the incidence of biopsy-proven acute rejection (BPAR) was 77% (37/48) and 66% (31/47) (P = 0.23) with treated BPAR in 50% and 23% (P < 0.01) in the everolimus and CNI groups, respectively; no episode led to hemodynamic compromise. Coronary allograft vasculopathy (CAV) assessed by coronary intravascular ultrasound was present in 53% (19/36) and 74% (26/35) of everolimus- and CNI-treated patients, respectively (P = 0.037). Graft dimensions and function were similar between the groups. Late adverse events were comparable. CONCLUSIONS: These results suggest that de novo heart transplant patients randomized to everolimus and low-dose CNI followed by CNI-free therapy maintain significantly better long-term renal function as well as significantly reduced CAV than patients randomized to standard CNI treatment. Increased BPAR in the everolimus group during year 1 did not impair long-term graft function.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Andreassen, Arne K.Oslo university hospital,Oslo Univ Hosp, Norway,Sahlgrens Univ Hosp, Sweden,Sahlgrenska University Hospital
(författare)
-
Andersson, BertSahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden
(författare)
-
Eiskjær, HansAarhus University Hospital,Aarhus Univ Hosp, Denmark
(författare)
-
Rådegran, GöranLund University,Lunds universitet,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Skåne University Hospital,Lund Univ, Sweden; Lund Univ, Sweden(Swepub:lu)med-grd
(författare)
-
Gude, EinarOslo university hospital,Oslo Univ Hosp, Norway
(författare)
-
Jansson, Kjell,1956-Linköpings universitet,Linköping University,Östergötland County Council,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Fysiologiska kliniken US(Swepub:liu)kjeja02
(författare)
-
Solbu, DagNovartis Norge AS, Norway
(författare)
-
Karason, KristjanSahlgrenska University Hospital
(författare)
-
Arora, SatishOslo university hospital,Oslo Univ Hosp, Norway
(författare)
-
Dellgren, GöranSahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden
(författare)
-
Gullestad, LarsUniversity of Oslo,Oslo university hospital,Oslo Univ Hosp, Norway; Univ Oslo, Norway; Univ Oslo, Norway
(författare)
-
University of CopenhagenCopenhagen University Hospital
(creator_code:org_t)
-
SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators
Sammanhörande titlar
-
Ingår i:Transplantation: LIPPINCOTT WILLIAMS & WILKINS104:1, s. 154-1641534-60800041-1337
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gustafsson, Finn
-
Andreassen, Arne ...
-
Andersson, Bert
-
Eiskjær, Hans
-
Rådegran, Göran
-
Gude, Einar
-
visa fler...
-
Jansson, Kjell, ...
-
Solbu, Dag
-
Karason, Kristja ...
-
Arora, Satish
-
Dellgren, Göran
-
Gullestad, Lars
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Transplantation
- Av lärosätet
-
Lunds universitet
-
Linköpings universitet